SF3B1突变型RNA错误剪接模型揭示UBA1为骨髓增生异常肿瘤的治疗靶点
研究利用MDS-SF3B1患者来源的SF3B1K700E与SF3B1WT同基因iPSC系分化为造血细胞,经全长RNA测序发现SF3B1K700E特异性UBA1错误剪接(UBA1ms),导致UBA1蛋白不稳定和总水平下降,使突变细胞对UBA1抑制剂TAK-243敏感;MDS患者CD34+测序数据证实MDS-SF3B1患者存在独特且普遍的UBA1ms;TAK-243选择性靶向MDS-SF3B1原代CD34+细胞并减少集落形成中的突变细胞数,而正常造血祖细胞不受影响。
要点
- SF3B1K700E同基因iPSC模型鉴定出UBA1特异性错误剪接(UBA1ms)。
- UBA1ms导致UBA1蛋白不稳定及总UBA1水平降低。
- TAK-243选择性靶向MDS-SF3B1原代CD34+细胞,正常造血祖细胞不受影响。
核心结论
- UBA1ms被定义为SF3B1突变细胞的新型治疗脆弱性,UBA1抑制为未来MDS-SF3B1治疗提供了潜在途径。
研究设计与样本
- 研究将来自MDS-SF3B1患者的SF3B1K700E与SF3B1WT同基因iPSC系分化为造血细胞,并采用全长RNA测序进行无监督剪接事件分析。
- 研究分析了来自MDS患者队列的CD34+ RNA测序数据,并在集落形成实验中检测了TAK-243对MDS-SF3B1原代CD34+细胞和正常造血祖细胞的作用。
主要发现
- 无监督剪接事件分析鉴定出SF3B1K700E特异性的UBA1错误剪接(UBA1ms)。
- UBA1ms引入蛋白不稳定性并降低总UBA1水平,使突变细胞对UBA1小分子抑制剂TAK-243敏感。
- MDS患者队列CD34+ RNA测序数据分析证实,UBA1ms在MDS-SF3B1患者中独特且普遍存在,而在其他剪接因子突变的MDS病例或健康对照中不存在。
- TAK-243选择性靶向MDS-SF3B1原代CD34+细胞,并在集落形成实验中减少突变细胞数量。
- 正常造血祖细胞不受TAK-243影响。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Myelodysplastic syndromes with somatic mutations in the splicing factor SF3B1 gene (MDS-SF3B1) result in RNA mis-splicing, erythroid dysplasia and ultimately refractory anemia. Precision medicine approaches for MDS-SF3B1 remain challenging due to both the complexity of the mis-splicing landscape and its evaluation in disease-accurate models. To uncover novel RNA mis-splicing events, isogenic SF3B1K700E and SF3B1WT iPSC lines from an MDS-SF3B1 patient were differentiated into hematopoietic cells and analyzed via unsupervised splicing event profiling using full-length RNA sequencing. This identified SF3B1K700E-specific mis-splicing of ubiquitin-like modifier activating enzyme 1 (UBA1), which encodes a key E1 protein at the apex of the ubiquitination cascade. UBA1 mis-splicing (UBA1ms) introduced protein instability and decreased total UBA1 levels, rendering mutated cells susceptible to the small-molecule UBA1 inhibitor TAK-243. Analysis of CD34+ RNA sequencing data from an MDS patient cohort confirmed unique and ubiquitous UBA1ms in MDS-SF3B1 patients, absent in other splicing factor-mutated MDS cases or healthy controls. TAK-243 selectively targeted MDS-SF3B1 primary CD34+ cells and reduced mutant cell numbers in colony-forming assays. In contrast, normal hematopoietic progenitor cells were unaffected. Altogether, we here define UBA1ms as a novel therapeutic vulnerability in SF3B1-mutant cells, introducing UBA1 inhibition as a potential avenue for future MDS-SF3B1 treatments.
引用
- Thier J, Hofmann S, Kirchhof KM, et al. SF3B1-mutant models of RNA mis-splicing uncover UBA1 as a therapeutic target in myelodysplastic neoplasms. Leukemia. 2025. PMID: 40858805. doi:10.1038/s41375-025-02740-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。